onkoserv

Indikation: Kolorektales Karzinom

zurück

2012

Patients' Expectations about Effects of Chemotherapy for Advanced Cancer

NEJM 367 (2012) 1616-1625

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study

Ann Oncol (2012) Online first 5. 10. 2012

A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer

Invest New Drugs 30 (2012) 2026-2031

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

J Clin Oncol 30 (2012) 3588-3595

Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)

Ann Oncol 23 (2012) 2619-2626

Oxaliplatin in Combination With Infusional 5-Fluorouracil as First-Line Chemotherapy for Elderly Patients With Metastatic Colorectal Cancer: A Phase II Study of the Spanish Cooperative Group for the Treatment of Digestive Tumors

Clin Colorect Cancer 11 (2012) 200-206

Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)

J Clin Oncol 30 (2012) online first 10. 9. 2012

The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study

Ann Surg Oncol 19 (2012) 2186-2194

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer

Clin Translat Oncol 14 (2012) 606-612

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

Ann Oncol 23 (2012) 2313-2318

A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer

Cancer 118 (2912) 4132-4138

Primary mFOLFOX6 Plus Bevacizumab Without Resection of the Primary Tumor for Patients Presenting With Surgically Unresectable Metastatic Colon Cancer and an Intact Asymptomatic Colon Cancer: Definitive Analysis of NSABP Trial C-10

J Clin Oncol 30 (2012) 3223-3228

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

J Clin Oncol 30 (2012) Online first 4. 9. 2012

Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: Results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601

Eur J Cancer (2012) Online first 27. 8. 2012

Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial

J Clin Oncol 30 (2012) 3353-3360

A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer

Acta Gastro-enterolog Belg 75 (2012)14-21

Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study

Ann Oncol 3 (2012) 1525-1530

Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study

J Clin Oncol 30 (2012) 2861-2868

Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

BMC Cancer 12 (2012) 349

Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study

Oncologist 17 (2012) 947-955